In Virginia, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date of injury or discovery. However, specific circumstances may affect this timeline. Consult a qualified attorney to evaluate your case and ensure compliance with applicable deadlines.
If you or a loved one took Reglan (metoclopramide) and now experience uncontrollable movements, you may be dealing with tardive dyskinesia. Medical research has long recognized that prolonged use of certain medications can lead to lasting neurological effects. This page outlines a patient history checklist to help veterans document Reglan exposure and potential symptoms.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its association with tardive dyskinesia (TD), a potentially irreversible movement disorder, has led to significant litigation. In Virginia, the statute of limitations for filing a Reglan-related TD claim is a critical factor for affected patients considering settlement. Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The condition can be disfiguring and may persist even after the offending drug is discontinued. Reglan's prescribing information explicitly warns that metoclopramide can cause TD, and the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug is contraindicated in patients with a history of TD, and healthcare providers are advised to use Reglan for the shortest possible duration, reassessing the need for continued therapy periodically (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks; for diabetic gastroparesis, treatment beyond 12 weeks should be avoided unless longer use is unavoidable, in which case routine monitoring for TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia. Chronic blockade can lead to upregulation of dopamine receptors and subsequent hypersensitivity, which is thought to underlie the development of TD. The FDA-approved label notes that metoclopramide may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect complicates the timeline between exposure and documented harm, as patients may not recognize symptoms until they become pronounced or persist after drug cessation.
Adequacy of warnings is a central issue in Reglan TD litigation. The boxed warning on Reglan's label clearly states the risk of TD and the importance of limiting treatment duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients were prescribed Reglan for extended periods, sometimes years, without appropriate monitoring or warnings about TD. The label also advises immediate discontinuation if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, evidence suggests that prescribers often failed to adhere to these guidelines, leading to prolonged exposure and increased risk. For settlement considerations, affected patients in Virginia must be aware of the statute of limitations, which generally requires filing a claim within two years of the date the injury was discovered or should have been discovered. This 'discovery rule' is crucial for TD cases, as symptoms may emerge months or years after Reglan use begins. The timeline between exposure and documented harm can vary widely; some patients develop TD within weeks, while others may not show symptoms until after years of use. The label notes that the risk of TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), but individual susceptibility also plays a role. Patients who develop TD after Reglan use may be eligible for settlement through mass tort litigation. Key factors in settlement negotiations include the severity of TD, the duration of Reglan use, and whether the prescribing physician provided adequate warnings. The FDA label explicitly states that Reglan is not recommended for pediatric patients due to TD risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), and this population may have stronger claims if prescribed off-label. Additionally, patients who used Reglan for longer than 12 weeks without documented medical necessity may have stronger cases, as the label limits use to 12 weeks for gastroesophageal reflux and advises against longer use for gastroparesis unless unavoidable (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
In Virginia, the statute of limitations for personal injury claims, including those related to Reglan TD, is generally two years from the date of injury discovery. However, if the injury was not immediately apparent, the clock may start when the patient reasonably should have known the cause. Given that TD can be misdiagnosed or attributed to other conditions, patients should seek legal counsel promptly upon diagnosis. Settlement amounts vary based on factors such as medical expenses, pain and suffering, and lost wages, but early filing is essential to preserve the right to compensation. In summary, Reglan's association with TD is well-documented, with clear warnings on the label about risk factors and recommended usage limits. Patients in Virginia who develop TD after Reglan use must act within the statute of limitations, typically two years from discovery of the injury. Understanding the timeline between exposure and harm, as well as the adequacy of warnings received, is critical for evaluating settlement options. Legal consultation is advised to navigate these complex medical and legal issues.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Virginia, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date the injury was discovered or should have been discovered. This 'discovery rule' is important because TD symptoms may not appear until months or years after Reglan use. Patients should consult an attorney promptly upon diagnosis to ensure their claim is filed within the legal timeframe.
Reglan (metoclopramide) can cause tardive dyskinesia through its dopamine D2 receptor antagonism in the basal ganglia. Chronic blockade leads to upregulation of dopamine receptors and hypersensitivity, resulting in involuntary movements. The risk increases with longer treatment duration and higher cumulative doses, as noted in the FDA label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.